Title
Hyperbaric oxygen therapy for traumatic brain injury.

Permalink
https://escholarship.org/uc/item/9tp691g4

Journal
Medical gas research, 1(1)

ISSN
2045-9912

Authors
Huang, Lei
Obenaus, Andre

Publication Date
2011-09-06

DOI
10.1186/2045-9912-1-21

Peer reviewed
Hyperbaric oxygen therapy for traumatic brain injury

Lei Huang1 and Andre Obenaus1,2,3,4,5*

Abstract
Traumatic brain injury (TBI) is a major public health issue. The complexity of TBI has precluded the use of effective therapies. Hyperbaric oxygen therapy (HBOT) has been shown to be neuroprotective in multiple neurological disorders, but its efficacy in the management of TBI remains controversial. This review focuses on HBOT applications within the context of experimental and clinical TBI. We also discuss its potential neuroprotective mechanisms. Early or delayed multiple sessions of low atmospheric pressure HBOT can reduce intracranial pressure, improve mortality, as well as promote neurobehavioral recovery. The complimentary, synergistic actions of HBOT include improved tissue oxygenation and cellular metabolism, anti-apoptotic, and anti-inflammatory mechanisms. Thus HBOT may serve as a promising neuroprotective strategy that when combined with other therapeutic targets for TBI patients which could improve long-term outcomes.

Keywords: intracranial pressure, metabolism, apoptosis, inflammation, tissue oxygenation, cerebral blood flow

Introduction
Hyperbaric oxygen therapy (HBOT) is a treatment by which 100% oxygen is administered to a patient at a pressure greater than atmospheric pressure at sea level (i.e. one atmosphere absolute, ATA) [1]. The increased partial pressure of oxygen (pO₂) within the blood and subsequent improved mitochondrial metabolism/tissue oxygenation constitutes the net effect of HBOT [2-6]. Given that the dissolved oxygen content in the plasma increases linearly after hemoglobin is 100% saturated [7,8], plasma bound oxygen can be used more readily than that bound to hemoglobin which enables tissue oxygen delivery even in the absence of red blood cells [7,9].

Thus, HBOT induces a much larger oxygen-carrying capacity in the blood that dramatically increases the driving force of oxygen diffusion to tissues. Although HBOT-induced cerebral vasoconstriction appears to be undesirable within the context of ischemic conditions [10,11] this may not be necessarily deleterious due to increased oxygen availability to injured tissues. HBOT may also counter vasodilation of the capillaries within hypoxic tissues, thereby minimizing collection of extravascular fluids (edema) which ultimately reduces brain vasogenic edema and the ensuing decrease in intracranial pressure (ICP) [5,12-14].

Emerging evidence has shown the neuroprotective effects of HBOT in a range of multiple injuries and/or disorders (Additional file 1, Table S1) [15]. The most common clinical applications include decompression sickness, carbon monoxide poisoning, minimization of radiation therapy induced tissue damage and enhancing skin grafts [1,16], which are all covered by insurance/Medicare. There are numerous “unapproved” uses of HBOT that focus on more complex neurological disorders, including autism, multiple sclerosis and stroke, which have shown promising results in experimental settings, but clinical efficacy is still elusive. Recent efforts have applied HBOT to traumatic brain injury [5,14,17]. While significant research on HBOT therapy has been undertaken (> 10,000 citations on PubMed), very little has been reported for HBOT within the setting of TBI (< 30 citations). We now briefly review the experimental and clinical HBO research relevant to TBI.

HBOT in animal models of TBI
Early experimental research focused on the effects of HBO on brain edema, ICP and cerebral blood flow...
(CBF). Dunn and colleagues first demonstrated the neuroprotective effects of hyperoxia in a dog freeze-lesion model of brain injury that simulated a brain contusion. Hyperoxia significantly improved outcomes by reducing mortality [18]. Reduced ICP (30% decrease) and CBF (19%) were also reported in a dog model of brain injury treated by HBOT (2 ATA for 4 hrs) [19]. The absence of changes in cerebrospinal fluid (CSF) lactate, a marker of brain injury, following HBOT further supported the notion that HBO improved tissue oxygen delivery despite the undesirable decrease in CBF subsequent to vasoconstriction [10]. Expanding on the original model, various methods (psyllium seed, extradural balloon) were used to induce brain edema in dogs followed by HBOT [20–23]. Using HBOT at 3 ATA for 45 min [20,21] or at 2 ATA for 4 hrs [22] resulted in a significant decrease (> 50%) in mortality relative to non-treated injured animals. They also reported significantly less brain edema [20] and reduced cisternal CSF pressure [21] in the HBOT groups. Sukoff and colleagues suggested that the improvement seen in their model was due to the effectiveness of HBOT against ischemia, secondary to the induced cerebral edema [21]. Hayakawa et al, however, found that HBOT (3 ATA for 1 hr) did not or barely changed CSF pressure and CBF in most injured dogs [23].

In a rat model of moderate fluid percussion injury, the neuroprotection afforded by HBOT translated into long term cognitive improvements, characterized by a shorter latency to find a hidden platform in Morris water maze (MWM) performance [2]. Within brain tissues, HBOT showed significant protection against hippocampal neuronal loss compared to normobaric oxygen treatment [2]. Importantly, there was no increased free radial peroxide and peroxyxinitrite production, suggesting the absence of oxygen toxicity after HBOT [2]. Studies in a model of cerebral ischemia concurred that HBOT did not exacerbate lipid peroxidation [24].

The aforementioned neuroprotective efficacy of HBOT was all achieved when intervention was administered during the acute phase (within hours) of post-TBI. The prolonged therapeutic time window of HBOT was further investigated in studies using a focal cortical weigh-drop model of TBI [25–27]. Wang and colleagues have demonstrated that multiple HBOT (3 ATA hourly for 3 or 5 days), delivered at latest 2 days post-injury resulted in significantly reduced overall neurological deficit scores and neuronal apoptosis within brain tissue. But the authors also showed that twelve hours post-TBI is the latest effective window for neuroprotection when a single episode of HBOT was delivered [27]. Moreover, Harch et al [25,26] have tested the effects of low pressure HBOT (90 min twice a day at 1.5 ATA) which started at 50 days after the initial brain injury for a total duration of 40 days. At end of the treatment (100 days post injury), MWM spatial learning performance in the HBOT groups improved significantly and was highly correlated with increased ipsilateral hippocampal blood volume (cerebrovascular density) measured by diaminobenzadine blood stain [25,26]. Given the well-described presence of angiogenesis in HBOT in other brain injury models [28,29], the authors suggested that angiogenesis was the most likely explanation for the HBOT-induced recovery of function. They claimed that coupling of “blood flow and metabolism” and “metabolism and function” were potential mechanisms, as both were increased in animals receiving HBOT. This hypothesis is consistent with the pattern of HBOT-induced increases in blood flow seen on single photon emission computed tomography brain imaging in patients with chronic TBI [30,31]. A caveat is that HBOT failed to improve forelimb placing function, likely due to the reported tissue loss within the sensorimotor cortex following TBI [26].

We recently investigated both prophylactic (pre-treatment) hyperbaric oxygen (HBO) strategy and HBOT (post-treatment) for treatment of repetitive mild traumatic brain injury (rmTBI) (personal communication: Drs. Lei Huang and Andre Obenaus). Repetitive mTBI is an important public health concern for sports athletes and active military personnel as subsequent injuries are thought to exacerbate existing neuropathology. Mild controlled cortical impact (CCI) was used to model rmTBI in adult rats. In rmTBI animals, a second mild CCI was delivered at the same location at 3 or 7 days after the initial impact. HBO pre-treatment or HBOT was given 1 hr daily at 2 ATA for 3 consecutive days either prior to or 24 hrs after the initial TBI, respectively. T2 weighted imaging (T2WI) and susceptibility weighted imaging (SWI) were acquired non-invasively from which lesion and hemorrhage volumes were quantified. Our results clearly demonstrated that both HBO pre-treatment and HBOT improved neuroimaging outcomes following rmTBI, in contrast to those seen in tissues without HBO intervention. There were significant reductions in the T2WI-derived lesion and SWI-identified hemorrhage volumes at 24 hrs after rmTBI (Figures 1, 2). The most dramatic neuroprotective effects were observed in animals receiving rmTBI 3 days apart where a 3-fold reduction in hemorrhage volumes was observed compared to Shams (Figure 2). Given that the pathophysiological processes underlying rmTBI likely involves cellular metabolic perturbations in the injured brain [32], a neuroprotective approach, namely, HBO pre-treatment or HBOT favoring cerebral aerobic metabolism could be beneficial. Similar findings have been reported in HBOT for human severe TBI [14].

**Clinical HBOT for human TBI**

A variety of human injuries and neurological diseases have applied HBOT to improve outcomes. More overt
neurological injuries, such as stroke or TBI have not been aggressively pursued, partly due to apparent or perceived contraindications. While a complete listing of the absolute and relative contraindications for clinical applications are beyond the scope of this review, it should be noted that certain drugs, fever and respiratory ailments limit clinical application of HBOT. However, within the realm of clinically applied HBOT for TBI very little research has been conducted. Enthusiasm for HBOT for brain injured patients was dampened by the findings of a meta-analysis of TBI patients receiving HBOT [33]. Their sobering conclusions were that the risk of death was reduced but there was no apparent change in clinical outcomes. However, as these authors acknowledged, variance in treatment protocols and the limited number of patients in the studies reviewed hampered their analysis. Based on their findings they suggested that HBOT could not be justified for TBI patients.

The poor clinical outcomes of earlier HBOT studies combined with the relative success of normobaric oxygen therapy (NBOT) in TBI have lead some to propose that normobaric oxygen therapy should be used preferentially in brain-injured patients. There are numerous studies that demonstrate an enhanced clinical outcomes by treatment with normobaric oxygen [34]. Much of the enthusiasm for use of NBOT is based on a prospective study of severe TBI patients [4]. Narotam and colleagues [35] evaluated brain tissue oxygen concentrations in patients with severe TBI. Using Licox oxygen probes, 139 patients were studied using a pO2 protocol that maintained brain oxygen levels to > 20 mm Hg. They elegantly demonstrated that normobaric oxygen therapy significantly reduced mortality, but moreover, they showed improved clinical outcomes at 6 mo post-severe TBI. A similar study found that hyperoxia improved the cerebral metabolic rate of oxygen in severe TBI patients using

![Figure 1 HBO reduces rmTBI lesion volumes](http://www.medicalgasresearch.com/content/1/1/21)
O15-postiron emission tomography, but they did not compare to HBOT treated patients [36]. Thus, at a minimum, NBOT could be beneficial for TBI patients.

The most extensive research into clinical application of HBOT for TBI patients has been conducted by the Rockswolds [5,14,17,37]. Almost 30 years ago they undertook one of the first clinical trials in evaluating the benefits of HBOT for severe head injured patients [17]. In that early study they demonstrated a 50% decrease in mortality but found no changes in the clinical outcome status (i.e. good recovery and moderate disability). As noted above, a meta-analysis of several studies concluded the same findings; reduced mortality but no change in clinical status [33].

While survival was increased, functional recovery was not changed, leading to questions about the timing of the HBOT. In addition, the mechanism(s) underlying HBOT and its effects on cerebral metabolism had not been previously established in severely brain-injured patients. In another prospective clinical trial, Rockswold et al [5], reported increased cerebral metabolic rate of oxygen and decreased lactate measured from cerebrospinal fluid after HBOT (1.5 ATA 1 hr/day every 24 hrs with a maximum of seven sessions). ICP was also reduced but a caveat was noted that these changes did not last till the next session [5]. It also serves to remind the reader that similar results had also been previously reported in NBOT [36].

Based on evidence that NBOT of human TBI patients appeared to have similar outcomes as patients who underwent HBOT, a follow-up study was conducted to compare these two groups after severe TBI to assess the efficacy of therapy [14]. It is important to note, that the standard of care is neither NBOT nor HBOT. Thus, their study design included controls (standard of care), normobaric (3 hrs 100% O₂) and HBOT (1.5 ATA for 60 min) that received their initial treatment within 24 hrs of a severe TBI. Treatments were then conducted daily for 3 consecutive days.

![Figure 2 HBOT reduces extravascular blood after rmTBI](Image)

HBO pre- and post-treatment improved susceptibility weighted imaging (SWI)-identified intracerebral hemorrhage following repetitive mild traumatic brain injury (rmTBI) 3 days apart. At 24 hrs after rmTBI, HBO pre- or post-treatment significantly ameliorated the hemorrhage (hypointensity, asterisks) compared to untreated animals, which persisted to 14 days after the initial mTBI.
The pO₂ levels within the brain were nearly 3 fold higher in the HBOT compared to the NBOT groups and significantly different from controls [14]. As previously reported, they found increased cerebral metabolic rate of oxygen, decreased lactate and decreased intracranial pressure. They also reported that HBOT increased cerebral blood flow. Perhaps the most important finding was that an indicator of mitochondrial dysfunction, lactate/pyruvate ratios, were significantly decreased only in the HBOT group. They also demonstrated no adverse outcomes or harmful effects in patients receiving HBOT [14]. Thus, HBOT for severe TBI, appears to improve cellular survival which was not observed in NBOT group.

Based on these limited studies, it is clear, that HBOT could be an effective therapy for clinical severe TBI. Compared to NBOT, HBOT assists in improving brain “functions”, such as cerebral metabolism and blood flow. However, additional studies are needed not only during the acute phase of the injury, but also long-term studies evaluating outcomes to determine if HBOT is beneficial to TBI patients.

**Putative mechanisms underlying the neuroprotection of HBOT following TBI**

Over the past several decades, the neuroprotective mechanisms of HBOT have been investigated in a variety of animal models of TBI. The initial work in dogs (see above) have shown the HBOT was able to increase tissue oxygen delivery [10] as well as to protect penumbra tissue from secondary ischemia [21]. Based on the dog model, a similar freeze-induced brain injury was conducted in rats to evaluate local cerebral glucose utilization using the autoradiographic 2-deoxyglucose technique. Compared to animals that underwent NBOT, a four-day HBOT course (2 ATA for 90 minutes daily) significantly reversed the depressed glucose utilization within gray matter ipsilateral to the lesion [38]. Interestingly, HBOT tended to decrease glucose utilization in the sham-operated animals. However, it was still uncertain whether the favorable outcomes were directly attributable to improved glucose metabolism associated with HBOT. HBO-improvements in tissue oxygenation and mitochondrial metabolic function were further investigated in a rat model of fluid percussion injury (FPI) [3]. HBOT (1 hr 1.5 ATA with 3 hrs 100% normobaric oxygen) treatments significantly improved, 1) brain tissue pO₂ (more than 6 fold) near the site of injury; 2) ex vivo brain tissue oxygen consumption (vO₂, more than 1 fold); and 3) recovery of synaptosomal mitochondrial metabolic activity [39,40].

Given that the prognosis of TBI clearly depends on the processes of cell death and survival that occur within the traumatized tissues, neuroprotective therapies need to mitigate and improve survival and function within the remaining viable perilesional brain tissue [41]. The neuroprotective effects of HBOT against secondary brain damage in the penumbra region have been extensively investigated [6,41-43]. Using a model of dynamic cortical deformation (DCD) to produce focal cerebral contusion in rats, HBOT (2 sessions at 2.8 ATA for 45 min/each) were administered at 3 hrs after TBI and compared to the effects of NBOT. There were significantly smaller lesion volumes and decreased numbers of terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL, a biomarker for apoptosis) positive cells after HBOT. Normobaric oxygen therapy (100%) also improved tissue measures but not to the extent found after HBOT [43]. The anti-apoptotic modulator, B-cell lymphoma (Bcl-2), was increased after HBOT and correlated to reduced tissue apoptosis [41]. Similar changes were found for B-cell lymphoma-extra large (Bcl-xl) expression, while the pro-inflammatory protein, B-cell lymphoma-associated X protein (Bax), was observed primarily in astrocytes instead of neurons. The ratio between pro-apoptotic Bax and anti-apoptotic Bcl-2/Bcl-xl proteins has been shown to act as a “rheostat” that sets the threshold [44] of susceptibility to apoptosis by competitively modulating the opening of the mitochondrial permeability transition pore (mPTP) [45,46]. Enhanced Bcl-2 expression inhibits the mPTP that subsequently preserves mitochondrial homeostasis and therefore the integrity of the electron transport chain [6]. Palzur et al thus hypothesized that HBOT-induced increases in Bcl-2 expression and the resultant increase in intracellular oxygen bio-availability may contribute both to preserve mitochondrial integrity and to reduce the activation of the mitochondrial mediated apoptotic pathway following TBI [6]. In the same animal model, HBOT (2.8 ATA for 45 min at 3 and 24 hrs post-injury) substantially facilitated the recovery of mPTP expression. Subsequently, TBI-induced injury to tissue morphology was reversed with enhanced neuronal survival and preserved axonal architecture within perilesional tissues [6]. Similar findings of improved mitochondrial redox after HBOT in the FPI model of TBI have also been reported [3]. The preservation of mitochondrial integrity by HBOT hindered the activation of mitochondria-associated apoptotic pathways by significantly lowering caspase 3 and 9, but not caspase 8 expression (critical for non-mitochondrial apoptotic pathway) in injured brain tissues [6]. These results underscore the importance of HBOT-induced reductions in delayed cell death within the tissue penumbra after TBI. Such, mechanisms echo the neuroprotection of HBO seen in brain ischemia and subarachnoid hemorrhage [47,48].

Acute inflammation also plays an important role in secondary brain damage after TBI. An influx of inflammatory cells induced by TBI provides the primary source of matrix metalloproteinases (MMPs) activity [49]. MMPs in the injured brain further play a deleterious role and promote cell death, including apoptosis [50]. The effects...
of HBOT on inflammatory infiltration and the expression of (MMPs) have been explored in a rat model of DCD. Both HBOT (2.8 ATA for 45 min at 3 hrs after injury and twice a day thereafter for 3 consecutive days) and NBOT significantly decreased myeloperoxidase-positive neutrophils within the traumatic penumbra, but HBOT had a more pronounced effect. HBOT also significantly reduced the elevation of MMP-9 expression associated with neutrophilic infiltration [42]. Thus, HBOT substantially decreases the harmful effects of inflammation by reducing MMP-9 over-expression that then results in a reduction of delayed cell death in penumbral tissues surrounding the site of injury. Interestingly, reduced MMP-9 has also been proposed to be the underlying mechanism associated with HBO pretreatment induced neuroprotection against TBI at high altitude in a rat model [51]. However, what is still unresolved is whether the decreased numbers of apoptotic cells following HBOT, is a direct anti-apoptotic effect or secondary consequence due to HBOT anti-inflammatory effects. Further studies are warranted to disclose the complex mechanisms underlying the neuroprotective effects of HBOT after TBI.

Conclusions
Translational research of HBOT in a variety of TBI models has shown neuroprotective effects in the absence of increased oxygen toxicity when administered at pressures less than 3 ATA. Due to the heterogeneity of human TBI, the efficacy of clinical HBOT and an optimal regimen for HBOT remains elusive. However, all human studies have involved severe TBI patients and it is likely that there may be increased efficacy in mild or moderate TBI patients. Recent clinical trials favor HBOT as promising safe therapeutic strategy for severe TBI patients. Although both NBOT and 1.5 ATA HBOT can be neuroprotective, HBOT exerts more robust and long-lasting effects in the absence of pulmonary or cerebral oxygen toxicity. The improved tissue oxygenation and cellular metabolism, anti-apoptotic as well as anti-inflammatory effects may constitute the multiple and complementary mechanisms underlying HBOT-induced neuroprotection.

Additional material

Additional file 1: Table S1: Current clinical uses for HBOT.
and 3.5 Atmospheres Upon Blood Gas Transport, Cerebral Circulation and Cerebral Metabolism. J Appl Physiol 1953, 5:471-486.
12. Sukoff MH, Ragatz RE. Hyperbaric Oxygenation for the Treatment of Acute Cerebral Edema. Neurosurgery 1982, 10:23-38.
13. Koshih K, Yokota A, Konda N, Kinoshita Y, Kawai K: Intracranial Pressure Responses During Hyperbaric Oxygen Therapy. Neurul Med Chr (Tokyo) 1991, 31:575-581.
14. Rockswold SB, Rockswold GL, Zaun DA, Zhang X, Cerra CE, Bergman TA, et al: A Prospective, Randomized Clinical Trial to Compare the Effect of Hyperbaric to Normobaric Hyperoxia on Cerebral Metabolism, Intracranial Pressure, and Oxygen Toxicity in Severe Traumatic Brain Injury. J Neurosurg 2011, 110:1080-1094.
15. Edwards ML: Hyperbaric Oxygen Therapy, Part 2: Application in Disease. J Vet Emerg Care (San Antonio) 2010, 20:289-297.
16. Mandal NG, White N, Wee MY: Carbon Monoxide Poisoning in a Parturient and the Use of Hyperbaric Oxygen for Treatment. Int J Obstet Anesth 2001, 10:71-74.
17. Rockswold GL, Ford SE, Anderson DC, Bergman TA, Sherman RE: Results of a Prospective Randomized Trial for Treatment of Severely Brain-Injured Patients with Hyperbaric Oxygen. J Neurosurg 1992, 76:929-934.
18. Dunn JE, Lawson DD: Effects of Hyperbaric and Hyperoxic Oxygen on Experimental Brain Injury. In Origins of Hyperbaric Medicine. Edited by: Brown WM, Cox BGS. Washington, DC: National Research Council, 1966;447-454.
19. Miller JD, Fitch W, Ledingham IW, Jennett WB: The Effect of Hyperbaric Oxygen on Experimentally Increased Intracranial Pressure. J Neurosurg 1970, 33:287-296.
20. Hollin SA, Sukoff MH, Jacobson JH: The Protective Effect of Hyperbaric Oxygenation in Experimentally Produced Cerebral Edema and Compression. Prog Brain Res 1966, 30:479-489.
21. Sukoff MH, Hollin SA, Espinosa OE, Jacobson JH: The Protective Effect of Hyperbaric Oxygenation in Experimental Cerebral Edema. J Neurosurg 1968, 29:236-241.
22. Moody RA, Mead CO, Raumsuke S, Mullan S: Therapeutic Value of Oxygen at Normal and Hyperbaric Pressure in Experimental Head Injury. J Neurosurg 1970, 33:1-54.
23. Hayakawa T, Kanai N, Kuroda R, Yamada R, Mogami H: Response of Cereborspinal Fluid Pressure to Hyperbaric Oxygenation. J Neurol Neurosurg Psychiatry 1971, 34:580-586.
24. Mink RB, Dutka AJ: Hyperbaric Oxygen after Global Cerebral Ischemia in Rabbbits Does Not Promote Brain Lipid Peroxidation. Crit Care Med 1995, 23:1398-1404.
25. Harch PG, Kriedt C, Van Meter KW, Sutherland RJ: Low Pressure Hyperbaric Oxygen Therapy Induces Cerebrovascular Changes and Improves Complex Learning/Memory in a Rat Open Head Bonk Chronic Brain Contusion Model. Undersea Hyp商 Med 1996, 23.
26. Harch PG, Krietk C, Van Meter KW, Sutherland RJ: Hyperbaric Oxygen Therapy Improves Spatial Learning and Memory in a Rat Model of Chronic Traumatic Brain Injury. Brain Res 2007, 1174:120-129.
27. Wang GH, Zhang XG, Jiang ZL, Li X, Peng LL, Li YC, et al: Neuroprotective Effects of Hyperbaric Oxygen Treatment on Traumatic Brain Injury in the Rat. J Neurotrauma 2010, 27:1733-1743.
28. Max RE, Ehler WJ, Tayapongsak P, Pierce LW: Relationship of Oxygen Dose to Angiogenesis Induction in Injured Tissue. Ann J Surg 1990, 160:519-524.
29. Myers RA, Max RE: Use of Hyperbaric Oxygen in Postradiation Head and Neck Surgery. Inc Monogr 1990, 151-157.
30. Golden ZL, Neubauer R, Golden CJ, Greene L, Marsh J, Mlko A: Improvement in Cerebral Metabolism in Chronic Brain Injury after Hyperbaric Oxygen Therapy. Int J Neurosci 2002, 112:119-131.
31. Neubauer RA, Gottlieb SF, Male A Jr: Identification of Hypometabolic Areas in the Brain Using Brain Imaging and Hyperbaric Oxygen. Clin Nucl Med 1992, 17:477-481.
32. Giza CC, Hovda DA: The Neurometabolic Cascade of Concussion. J Athl Trauma 2001, 36:238-235.
33. Bennett AH, Trytko B, Jonker B: Hyperbaric Oxygen Therapy for the Adjunctive Treatment of Traumatic Brain Injury. Cochrane Database Syst Rev 2004, CD004609.
34. Kumaria A, Tolas CM: Normobaric Hyperoxia Therapy for Traumatic Brain Injury and Stroke: A Review. Br J Neurosurg 2009, 23:576-584.
35. Narotam PK, Morrison JF, Nathoo N: Brain Tissue Oxygen Monitoring in Traumatic Brain Injury and Major Trauma: Outcome Analysis of a Brain Tissue Oxygen-Directed Therapy. J Neurosurg 2009, 111:672-682.
36. Nortje J, Cotes JP, Timofeev I, Fryer TD, Agbibia FJ, Smelevski P, et al: Effect of Hyperoxia on Regional Oxygenation and Metabolism after Severe Traumatic Brain Injury: Preliminary Findings. Crit Care Med 2008, 36:273-281.
37. Rockswold SB, Rockswold GL, Defillo A: Hyperbaric Oxygen in Traumatic Brain Injury. Neurosurg Rev 2007, 29:162-172.
38. Conteras FL, Kadekarao M, Eisenberg HM: The Effect of Hyperbaric Oxygen on Glucose Utilization in a Freeze-Traumatized Rat Brain. J Neurosurg 1988, 68:137-141.
39. Azbil RD, Mu X, Bruce-Keller AJ, Mattson MP, Springer JE: Impaired Mitochondrial Function, Oxidative Stress and Altered Antioxidant Enzyme Activities Following Traumatic Spinal Cord Injury. Brain Res 1997, 765:283-290.
40. Springer JE, Azbil RD, Carlson SL: A Rapid and Sensitive Assay for Measuring Mitochondrial Metabolic Activity in Isolated Neural Tissue. Brain Res Brain Res Protoc 1998, 2:259-263.
41. Vodavsky E, Palzur E, Feinsod M, Soustiel JF: Evaluation of the Apoptosis-Related Proteins of the Bcl-2 Family in the Traumatic Penumara Area of the Rat Model of Cerebral Contusion, Treated by Hyperbaric Oxygen Therapy: A Quantitative Immunohistochemical Study. Acta Neuropathol 2005, 110:120-126.
42. Vodavsky E, Palzur E, Soustiel JF: Hyperbaric Oxygen Therapy Reduces Neuroinflammation and Expression of Matrix Metalloproteinase-9 in the Rat Model of Traumatic Brain Injury. Neuropharmacol Appl Neuropat 2006, 32:40-50.
43. Palzur E, Vodavsky E, Mulla H, Arieli R, Feinsod M, Soustiel JF: Hyperbaric Oxygen Therapy for Reduction of Secondary Brain Damage in Head Injury: An Animal Model of Brain Contusion. J Neurotrauma 2004, 21:41-48.
44. Korsmeyer SJ, Shutter JR, Veis DJ, Merry DE, Ottvai ZN: Bcl-2/Bax: A Rheostat That Regulates an Anti-Oxidant Pathway and Cell Death. Semm Cancer Biol 1993, 4:327-332.
45. Sharpe JC, Arnould D, Youle RJ: Control of Mitochondrial Permeability by Bcl-2 Family Members. Biochim Biophys Acta 2004, 1644:107-113.
46. Shimizu S, Narta M, Tsumiyo Y: Bcl-2 Family Proteins Regulate the Release of Apoptorigenic Cytochrome C by the Mitochondrial Channel Vdac. Nature 1999, 399:483-487.
47. Calvert JW, Zhou C, Nanda A, Zhang JH: Effect of Hyperbaric Oxygen on Apoptosis in Neonatal Hypoxia-Ischemia Rat Model. J Appl Physiol 2003, 95:2072-2080.
48. Yin D, Zhou C, Kusakia S, Calvert JW, Parent AD, Nanda A, et al: Inhibition of Apoptosis by Hyperbaric Oxygen in a Rat Focal Cerebral Ischemic Model. J Cereb Blood Flow Metab 2003, 23:853-864.
49. Cuozzo ML, Opdenaker G: Plasminogen Activators and Matrix Metalloproteases, Mediators of Extracellular Proteolysis in Inflammatory Demyelination of the Central Nervous System. J Neuroimmunol 1999, 94:1-14.
50. Wennemer A, Holm S, Mathiesen T: Characterization of Bax and Bcl-2 in Apoptosis after Experimental Traumatic Brain Injury in the Rat. Acta Neuropathol 2003, 105:281-288.
51. Hu SJ, Hu R, Li F, Liu Z, Xia YZ, Cui GY, et al: Hyperbaric Oxygen Preconditioning Protects against Traumatic Brain Injury at High Altitude. Acta Neurochir Suppl 2008, 105:191-196.